查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1316936

癌症免疫治疗市场：按产品、功能和最终用户划分 - 2023-2030 年全球预测

Cancer Immunotherapy Market by Product, Function, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球癌症免疫治疗市场预计将大幅成长，2023年将达到733.8亿美元，2030年将达到1,071.1亿美元，年复合成长率为5.53%。

FPNV定位矩阵

FPNV定位矩阵对于评估全球癌症免疫治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.癌症免疫治疗的全球市场规模与预测为何？

2.在预测期内，COVID-19对全球癌症免疫治疗市场的阻碍因素和影响为何？

3. 在预测期内，全球癌症免疫治疗市场需要投资哪些产品/细分市场/应用/领域？

4.你们在全球癌症免疫治疗市场的竞争策略是什么？

5. 全球癌症免疫治疗市场的技术趋势和法律规范是什么？

6.全球癌症免疫治疗市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入全球癌症免疫疗法市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症患者的盛行率正在上升
      • 先进抗癌药物的采用增加
      • 癌症治疗研发投资激增
    • 抑制因素
      • 资本集中治疗和程序
    • 机会
      • 药物开发过程中生物资讯学工具的广泛开发
      • 癌症免疫治疗临床试验数量增加
    • 任务
      • 限制免疫反应的癌症併发症
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章癌症免疫治疗市场：副产品

  • 细胞疗法
    • 嵌合抗原受体T细胞疗法
    • 树突状细胞
  • 检查点抑制剂
    • 细胞毒性T淋巴球相关蛋白4
    • 程序性死亡 1 和程序性死亡配体 1
  • 免疫调节剂
    • 粒细胞-巨噬细胞集落刺激因子
    • 干扰素
    • 白血球介素
    • 溶瘤病毒
  • 单株抗体
    • 双特异性单株抗体
    • 缀合单株抗体
    • 裸单株抗体
  • 疫苗
    • 预防性疫苗
    • 治疗性疫苗

第7章癌症免疫治疗市场：依功能分类

  • 乳癌
  • 大肠直肠癌
  • 头颈癌
  • 肺癌
  • 黑色素瘤
  • 多发性骨髓瘤
  • 摄护腺癌

第8章癌症免疫治疗市场：依最终用户分类

  • 癌症研究
  • 诊所
  • 医院

第9章美洲癌症免疫治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太癌症免疫治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章欧洲、中东和非洲癌症免疫治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第12章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-4330CC794A75

The Global Cancer Immunotherapy Market is forecasted to grow significantly, with a projected USD 73.38 billion in 2023 at a CAGR of 5.53% and expected to reach a staggering USD 107.11 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Immunotherapy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Immunotherapy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. The Cell Therapies is further studied across Chimeric Antigen Receptor T Cell Therapy and Dendritic Cells. The Checkpoint Inhibitors is further studied across Cytotoxic T-Lymphocyte-Associated Protein-4 and Programmed Death 1 & Programmed Death Ligand 1. The Immunomodulators is further studied across Granulocyte-Macrophage Colony-Stimulating Factor, Interferons, Interleukins, and Oncolytic Virus. The Monoclonal Antibodies is further studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Naked Monoclonal Antibodies. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines. The Checkpoint Inhibitors is projected to witness significant market share during forecast period.

Based on Function, market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer. The Melanoma is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Cancer Research Institutes, Clinics, and Hospitals. The Cancer Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Immunotherapy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Immunotherapy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Immunotherapy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Immunotherapy Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Immunotherapy Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Immunotherapy Market?

6. What is the market share of the leading vendors in the Global Cancer Immunotherapy Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Immunotherapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer Immunotherapy Market, by Product, 2022 vs 2030
  • 4.3. Cancer Immunotherapy Market, by Function, 2022 vs 2030
  • 4.4. Cancer Immunotherapy Market, by End-User, 2022 vs 2030
  • 4.5. Cancer Immunotherapy Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer patients worldwide
      • 5.1.1.2. Increasing adoption of advanced cancer therapeutics
      • 5.1.1.3. Surging investments in research and development activities of cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment and procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Extensive development of bioinformatics tools in drug development process
      • 5.1.3.2. Growing number of clinical trials for cancer immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Complications in cancer limiting the immune response
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Cancer Immunotherapy Market, by Product

  • 6.1. Introduction
  • 6.2. Cell Therapies
    • 6.2.1. Chimeric Antigen Receptor T Cell Therapy
    • 6.2.2. Dendritic Cells
  • 6.3. Checkpoint Inhibitors
    • 6.3.1. Cytotoxic T-Lymphocyte-Associated Protein-4
    • 6.3.2. Programmed Death 1 & Programmed Death Ligand 1
  • 6.4. Immunomodulators
    • 6.4.1. Granulocyte-Macrophage Colony-Stimulating Factor
    • 6.4.2. Interferons
    • 6.4.3. Interleukins
    • 6.4.4. Oncolytic Virus
  • 6.5. Monoclonal Antibodies
    • 6.5.1. Bispecific Monoclonal Antibodies
    • 6.5.2. Conjugated Monoclonal Antibodies
    • 6.5.3. Naked Monoclonal Antibodies
  • 6.6. Vaccines
    • 6.6.1. Prophylactic Vaccines
    • 6.6.2. Therapeutic Vaccines

7. Cancer Immunotherapy Market, by Function

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Head & Neck Cancer
  • 7.5. Lung Cancer
  • 7.6. Melanoma
  • 7.7. Multiple Myeloma
  • 7.8. Prostate Cancer

8. Cancer Immunotherapy Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Cancer Immunotherapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Immunotherapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CANCER IMMUNOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER IMMUNOTHERAPY MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 5. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2022 VS 2030 (%)
  • FIGURE 6. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 7. CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. CANCER IMMUNOTHERAPY MARKET DYNAMICS
  • FIGURE 9. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 20. CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 25. CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 29. CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND CANCER IMMUNO